Corrigendum to “Schisandrin B alleviates diabetic nephropathy through suppressing excessive inflammation and oxidative stress” (Biochemical and Biophysical Research Communications (2019) 508(1) (243–249), (S0006291X18325580), (10.1016/j.bbrc.2018.11.128))

doi:10.1016/j.bbrc.2019.02.027

科研成果详情

名称	Corrigendum to “Schisandrin B alleviates diabetic nephropathy through suppressing excessive inflammation and oxidative stress” (Biochemical and Biophysical Research Communications (2019) 508(1) (243–249), (S0006291X18325580), (10.1016/j.bbrc.2018.11.128))
作者	Mou, Zhenxin 1; Feng, Zhiguo 1; Xu, Zheng 1; Zhuang, Fei 1,2,3; Zheng, Xuyong1,4; Li, Xiaokun1; Qian, Jianchang1; Liang, Guang1
发表期刊	Biochemical and Biophysical Research Communications;
语种	英语
原始文献类型	Erratum
摘要	It has been brought to our attention that the result statment controdicts Fig. 4E. The authors would like to apologise for any inconvenience caused. In the section of “2.4. SchB suppresses inflammation and oxidative stress in diabetic mice”, we stated that “Consistent with the above data, we found that kidney tissue of diabetic mice had downregulated Nrf2 expression, and SchB prevented this downregulation”. However, we shown the nucleus translocation of Nrf2 in Fig. 4E. The figure has been corrected, and shown below:[Figure presented] Fig. 4. SchB obviously inhibits inflammation and oxidative stress in DN. An Immunoblotting assay was performed to probe IkBa and VCAM-1. B Detect the transcription level of TNF-a and VCAM-1 using real-time qPCR as described in methods. C Immunohistochemistry assay was set up to determine the expression of TNF-a in tissue. D Oxidative stress was evaluated by using DHE staining (red). E Determine the expression level of Nrf2 by immunoblotting assay. The images were quantified and plotted accordingly. The images were captured (200 × magnification). #p < 0.05, ###p < 0.001, T1DM vs control (Ctrl); p < 0.05, p < 0.01, **p < 0.001, T1DM + SchB vs T1DM.
出版者	ACADEMIC PRESS INC ELSEVIER SCIENCE
ISSN	0006-291X
EISSN	1090-2104
卷号	511
期号	1
页码	199-200
DOI	10.1016/j.bbrc.2019.02.027
页数	2
WOS类目	Biochemistry & Molecular Biology ; Biophysics
WOS研究方向	Biochemistry & Molecular Biology ; Biophysics
WOS记录号	WOS:000460849800032
收录类别	SCOPUS ; SCIE
发布日期	2019-03-26
URL	查看原文
PubMed ID	30765223
通讯作者地址	[Qian, Jianchang]Wenzhou Med Univ, Sch Pharmaceut Sci, Chem Biol Res Ctr, Wenzhou 325035, Zhejiang, Peoples R China.
Scopus学科分类	Biophysics;Biochemistry;Molecular Biology;Cell Biology
SCOPUSEID	2-s2.0-85061339732
引用统计
文献类型	其他
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/185529
专题	药学院（分析测试中心）附属第二医院第二临床医学院，附属第二医院、育英儿童医院第一临床医学院（信息与工程学院）、附属第一医院_药学部
通讯作者	Qian, Jianchang
作者单位	1.Wenzhou Med Univ, Sch Pharmaceut Sci, Chem Biol Res Ctr, Wenzhou 325035, Zhejiang, Peoples R China; 2.Wenzhou Med Univ, Dept Endocrinol, Diabet Ctr, Affiliated Hosp 2, Wenzhou, Zhejiang, Peoples R China; 3.Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Zhejiang, Peoples R China; 4.Wenzhou Med Univ, Dept Pharm, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China
第一作者单位	药学院（分析测试中心）
通讯作者单位	药学院（分析测试中心）
推荐引用方式 GB/T 7714	Mou, Zhenxin,Feng, Zhiguo,Xu, Zheng,et al. Corrigendum to “Schisandrin B alleviates diabetic nephropathy through suppressing excessive inflammation and oxidative stress” (Biochemical and Biophysical Research Communications (2019) 508(1) (243–249), (S0006291X18325580), (10.1016/j.bbrc.2018.11.128)). 2019.